Status:

RECRUITING

Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath

Lead Sponsor:

ChromX Health

Collaborating Sponsors:

The First Affiliated Hospital of Guangzhou Medical University

First People's Hospital of Foshan

Conditions:

Pulmonary Nodules, Multiple

Pulmonary Nodules, Solitary

Eligibility:

All Genders

18-80 years

Brief Summary

The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) markers. This model aims to accurately differentiate ...

Detailed Description

This is a prospective, cross-sectional, and observational cohort study aiming at recruiting 3000 participants with pulmonary nodules ranging from 5 to 30 mm in diameter. Prior to invasive surgery, exh...

Eligibility Criteria

Inclusion

  • 18-80 years old;
  • Pulmonary nodules were detected through low-dose spiral CT, chest CT conventional scan, or high-resolution thin-layer CT examination, with a maximum diameter of 5-30 mm, including solid nodules and ground glass nodules;
  • Patients require pulmonary nodule resection to define the type of nodule pathology;
  • The Patients have not yet used any drugs for tumor treatment;
  • Patients and/or family members are able to understand the research protocol and are willing to participate in this study, providing written informed consent.

Exclusion

  • The maximum diameter of pulmonary nodules is greater than 30 mm;
  • Patients are unable to determine the pathological diagnosis of pulmonary nodules after surgical resection or biopsy;
  • Patients with recurrent lung cancer;
  • Patients who have undergone lung transplantation or lobectomy;
  • Individuals who currently or have a history of malignant tumors;
  • Patients in the acute phase of inflammation or in need of intensive care in the above selected disease groups;
  • Individuals with severe liver and kidney dysfunction;
  • Mental illness patients (such as severe dementia, schizophrenia, severe depression, manic depressive psychosis, etc.);
  • Confirmed HIV patients;
  • Pregnant or lactating women;
  • Patients or family members are unable to understand the conditions and objectives of this study.
  • The patient is unwilling or unable to personally sign the informed consent form.

Key Trial Info

Start Date :

June 30 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 30 2027

Estimated Enrollment :

3000 Patients enrolled

Trial Details

Trial ID

NCT06518655

Start Date

June 30 2024

End Date

June 30 2027

Last Update

December 24 2025

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

2

First People's Hospital of Foshan

Foshan, Guangdong, China, 528000

3

The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China, 510140

4

Liwan District Central Hospital

Guangzhou, Guangdong, China, 510175